Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Cancidas — CASPOFUNGIN ACETATE
Application NDA206110 (NDA)
Atropine Sulfate — ISOPTO ATROPINE
Application NDA208151 (NDA)
Diprivan — DIPRIVAN
Application NDA019627
Naropin — NAROPIN
Application NDA020533
Bloxiverz — NEOSTIGMINE METHYLSULFATE
Application NDA203629 (NDA)
Atropine Sulfate — ATROPINE (AUTOINJECTOR)
Application NDA212319 (NDA)
Naropin — NAROPIN
Application NDA020533
Atropine Sulfate — ATROPINE SULFATE
Application NDA209260 (NDA)
Faslodex — FULVESTRANT
Application NDA210063 (NDA)
Faslodex — FULVESTRANT
Application NDA210326 (NDA)
Atropine Sulfate — ATROPINE SULFATE
Application NDA214652 (NDA)
Diprivan — DIPRIVAN
Application NDA019627
Diprivan — DIPRIVAN
Application NDA019627
Naropin — NAROPIN
Application NDA020533
Naropin — NAROPIN
Application NDA020533
Atropine Sulfate — ATROPINE SULFATE
Application NDA213581 (NDA)
Diprivan — DIPRIVAN
Application NDA019627
Esmeron — ROCURONIUM BROMIDE
Application NDA219108 (NDA)
Esmeron — ROCURONIUM BROMIDE
Application NDA217472 (NDA)
Glycophos — GLYCOPHOS
Application NDA220381 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)